Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B‐cell non‐Hodgkin lymphoma
Wiseman, Gregory A., Maurer, Matthew J. , Micallef, Ivana N. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Inwards, David J. , Porrata, Luis F. , Link, Brian K. , Johnston, Patrick B. , Allmer, Cristine, Asmann, Yan W. , Ballas, Zuhair K. , Smith, Brian J., Weiner, George J. , Witzig, Thomas E. , Habermann, Thomas M. , Colgan, Joseph P. , Zent, Clive S. , Shanafelt, Tait D. , Gupta, Mamta , Smith, Brian J., Maurer, Matthew , Link, Brian K , Weiner, George

American Journal of Hematology | April 26, 2013 | Volume: 88 | Issue: 7 | Pages: 589-593

10.1002/ajh.23460 | PMID 23619698 Get It

Radioimmunotherapy (RIT) for relapsed indolent non‐Hodgkin lymphoma produces overall response rates (ORR) of 80% with mostly partial remissions. Synthetic CpG oligonucleotides change the phenotype of malignant B‐cells, are immunostimulatory, and can produce responses when injected intratumorally and combined with conventional radiation. In this phase I trial, we tested systemic administration of both CpG and RIT. Eligible patients had biopsy‐proven previously treated CD20+ B‐cell NHL and met criteria for RIT. Patients received rituximab 250 mg/m2 days 1,8, and 15; 111In‐ibritumomab tiuxetan days 1, 8; CpG 7909 days 6, 13, 20, 27; and 0.4 mCi/kg of 90Y‐ibritumomab tiuxetan day 15. The doses of CpG 7909 tested were 0.08, 0.16, 0.32 (six patients each) and 0.48 mg/kg (12 patients) IV over 2 hr without dose limiting toxicity. The ORR was 93% (28/30) with 63% (19/30) complete remission (CR); median progression free survival of 42.7 months (95% CI 18‐NR); and median duration of response (DR) of 35 months (4.6–76+). Correlative studies demonstrated a decrease in IL10 and TNFα, and an increase in IL1β, in response to therapy. CpG 7909 at a dose of 0.48 mg/kg is safe with standard RIT and produces a high CR rate and long DR; these results warrant confirmation. Am. J. Hematol. 88:589–593, 2013. © 2013 Wiley Periodicals, Inc.
ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions
Verghese, Philip B. , Castellano, Joseph M. , Garai, Kanchan , Jiang, Hong , Shah, Aarti R., Bu, Guojun , Frieden, Carl , Wang, Yinong , Holtzman, David M. , Bu, Guojun

Proceedings of the National Academy of Sciences | April 26, 2013 | Volume: 110 | Issue: 19 | Pages: No page available

10.1073/pnas.1220484110 | PMID 23620513 Get It

Significance It has been proposed that differential physical interactions of apolipoprotein E (apoE) isoforms with soluble amyloid-β (Aβ) in brain fluids influence the metabolism of Aβ, providing a major mechanism to account for how APOE influences Alzheimer’s disease risk. The current study challenges this proposal and clearly shows that lipoproteins containing apoE isoforms are unlikely to play a significant role in Aβ metabolism by binding directly to Aβ in physiological fluids such as cerebrospinal fluid or interstitial fluid. Our in vitro and in vivo results suggest that apoE isoforms influence Aβ metabolism by competing for the same clearance pathways within the brain.
Tips and Tricks for MR Angiography of Pediatric and Adult Congenital Cardiovascular Diseases
Young, Phillip M. , McGee, Kiaran P. , Pieper, Matthew S., Binkovitz, Larry A. , Matsumoto, Jane M., Kolbe, Amy B. , Foley, Thomas A. , Julsrud, Paul R.

American Journal of Roentgenology | April 25, 2013 | Volume: 200 | Issue: 5 | Pages: 980-988

10.2214/ajr.12.9632 | PMID 23617479 Get It

UIP Diagnosed at Surgical Lung Biopsy, 2000–2009: HRCT Patterns and Proposed Classification System
Gruden, James F. , Panse, Prasad M., Leslie, Kevin O., Tazelaar, Henry D. , Colby, Thomas V. , Tazelaar, Henry D.

American Journal of Roentgenology | April 25, 2013 | Volume: 200 | Issue: 5 | Pages: W458-W467

10.2214/ajr.12.9437 | PMID 23617514 Get It

Atlas of Pulmonary Vascular Imaging
Stoffey, Robert D.

American Journal of Roentgenology | April 25, 2013 | Volume: 200 | Issue: 5 | Pages: W531-W531

10.2214/ajr.12.10300 Get It

Allaying and alleviating amyloid agony and anxiety
Gertz, Morie A.

Blood | April 25, 2013 | Volume: 121 | Issue: 17 | Pages: 3301-3302

10.1182/blood-2013-03-491746 | PMID 23620568 Get It

Comparison of three staining methods to identify eosinophils in formalin‐fixed canine skin
Gomes, P., Torres, Sheila M. F. , Plager, Douglas A., Jessen, Carl R., Lee, James J.

Veterinary Dermatology | April 25, 2013 | Volume: 24 | Issue: 3 | Pages: 323

10.1111/vde.12029 | PMID 23617395 Get It

BackgroundStudies comparing the ability of staining methods to detect eosinophils in formalin‐fixed canine skin are lacking.Hypothesis/ObjectivesThe aim of this study was to compare the effectiveness of eosinophil peroxidase monoclonal antibody (EPXmAb), Luna and haematoxylin and eosin (H&E) to detect eosinophils in fixed canine skin by assessing the following parameters: (i) specificity of eosinophil staining; (ii) extracellular eosinophil granule staining; (iii) tissue background staining; (iv) contrast between eosinophil and surrounding tissue staining; and (v) differences in the number of eosinophils detected by each stain.MethodsThree serial sections of formalin‐fixed, paraffin‐embedded tissues of predominantly eosinophilic skin diseases (n = 8), noneosinophilic skin diseases (n = 7) and normal canine skin (n = 1) were stained with the three stains. Each parameter was independently assessed and scored by two investigators.ResultsLuna and EPXmAb were specific in detecting eosinophils. The EPXmAb was significantly more effective than Luna (P < 0.001) and H&E (P < 0.001) in its ability to detect extracellular eosinophil granules (i.e. to detect intact and released eosinophil granules). The EPXmAb showed significantly less background staining compared with Luna (P = 0.0005). Moreover, significantly more stain contrast was noted with EPXmAb compared with Luna (P = 0.003) and H&E (P < 0.001). There was no significant difference between the mean eosinophil counts among the three stains.Conclusion and clinical importanceThe three stains were shown to be useful to detect and quantify eosinophils in fixed canine skin. The EPXmAb‐based immunohistochemical stain proved to be a novel tool to detect eosinophils in canine skin.
HIGHLIGHTING DIFFERENCES BETWEEN CONDITIONAL AND UNCONDITIONAL QUANTILE REGRESSION APPROACHES THROUGH AN APPLICATION TO ASSESS MEDICATION ADHERENCE
Borah, Bijan J. , Basu, Anirban

Health Economics | April 25, 2013 | Volume: 22 | Issue: 9 | Pages: 1052-1070

10.1002/hec.2927 | PMID 23616446 Get It

ABSTRACTThe quantile regression (QR) framework provides a pragmatic approach in understanding the differential impacts of covariates along the distribution of an outcome. However, the QR framework that has pervaded the applied economics literature is based on the conditional quantile regression method. It is used to assess the impact of a covariate on a quantile of the outcome conditional on specific values of other covariates. In most cases, conditional quantile regression may generate results that are often not generalizable or interpretable in a policy or population context. In contrast, the unconditional quantile regression method provides more interpretable results as it marginalizes the effect over the distributions of other covariates in the model. In this paper, the differences between these two regression frameworks are highlighted, both conceptually and econometrically. Additionally, using real‐world claims data from a large US health insurer, alternative QR frameworks are implemented to assess the differential impacts of covariates along the distribution of medication adherence among elderly patients with Alzheimer's disease. Copyright © 2013 John Wiley & Sons, Ltd.
Transoral laser microsurgery for the unknown primary: Role for lingual tonsillectomy
Nagel, Thomas H. , Hinni, Michael L., Hayden, Richard E. , Lott, David G.

Head & Neck | April 25, 2013 | Volume: 36 | Issue: 7 | Pages: 942-946

10.1002/hed.23372 | PMID 23616406 Get It

BackgroundWe conducted a retrospective review of patients with unknown primary head and neck cancer who underwent a transoral laser microsurgery (TLM)‐assisted search for an occult tumor.MethodsFifty‐two patients at a single center with unknown primaries of squamous cell carcinoma (SCC) were treated with a surgical algorithm.ResultsThe overall rate of primary tumor identification was 75% (39 of 52 patients). When selecting those cases in which a TLM algorithm with lingual tonsillectomy was utilized, the detection rate was 86% (31 of 36). Tumors were most commonly found in the lingual (65.0%) and palatine tonsils (27.5%). When directed biopsies did not locate a tumor, a higher yield was obtained with the addition of a lingual tonsillectomy in 8 patients.ConclusionA surgical algorithm for the unknown primary that includes TLM‐assisted techniques, including a lingual tonsillectomy, offers the greatest likelihood of successfully detecting the location of occult primary tumors. © 2014 Wiley Periodicals, Inc. Head Neck 36: 942–946, 2014
BRCA1/2 Sequence Variants of Uncertain Significance: A Primer for Providers to Assist in Discussions and in Medical Management
Lindor, Noralane M. , Goldgar, David E., Tavtigian, Sean V. , Goldgar, David E., Plon, Sharon E. , Couch, Fergus J.

The Oncologist | April 25, 2013 | Volume: 18 | Issue: 5 | Pages: 518-524

10.1634/theoncologist.2012-0452 | PMID 23615697 Get It

AbstractIntroduction.DNA variants of uncertain significance (VUS) are common outcomes of clinical genetic testing for susceptibility to cancer. A statistically rigorous model that provides a pathogenicity score for each variant has been developed to aid in the clinical management of patients undergoing genetic testing.Methods.The information in this article is derived from multiple publications on VUS in BRCA genes, distilled for communicating with clinicians who may encounter VUS in their practice.Results.The posterior probability scores for BRCA1 or BRCA2 VUS, calculated from a multifactorial likelihood model, are explained, and links for looking up specific VUS are provided. The International Agency on Cancer Research (IARC) of the World Health Organization has proposed a simple five-tier system for clinical management that is not widely known to clinicians. Classes 1 and 2 in this system are managed as neutral variants, classes 4 and 5 are managed as pathogenic variants, and class 3 variants still have insufficient evidence to move to either end of this scale and, thus, cannot be used in medical management.Conclusions.Development of models that integrate multiple independent lines of evidence has allowed classification of a growing number of VUS in the BRCA1 and BRCA2 genes. The pathogenicity score that is generated by this model maps to the IARC system for clinical management, which will assist clinicians in the medical management of those patients who obtain a VUS result upon testing.